[February 27, 2017] |
|
Global Infectious Diseases Partnering 2010-2017: Deal Trends, Players and Financials Report - Research and Markets
Research and Markets has announced the addition of the "Global
Infectious Diseases Partnering 2010-2017: Deal trends, players and
financials" report to their offering.
Global Infectious Diseases Partnering 2010 to 2017 is intended to
provide the reader with an in-depth understanding and access to
Infectious Diseases trends and structure of deals entered into by
leading companies worldwide.
Most of the deals included within the report occur when a licensee
obtains a right or an option right to license a licensor's product or
technology. More often these days these deals tend to be multi-component
including both a collaborative R&D and a commercialization of outcomes
element.
The report takes readers through the comprehensive Infectious Diseases
disease deal trends, key players and top deal values allowing the
understanding of how, why and under what terms companies are currently
entering Infectious Diseases deals.
The report presents financial deal terms values for Infectious Diseases
deals, where available listing by overall headline values, upfront
payments, milestones and royalties enabling readers to analyse and
benchmark the value of current deals.
Report scope:
-
Trends in Infectious Diseases dealmaking in the biopharma industry
since 2010
-
Analysis of Infectious Diseases deal structure
-
Access to headline, upfront, milestone and royalty data
-
Access to hundredsof Infectious Diseases deal contract documents
-
Comprehensive access to over 3500 Infectious Diseases deal records
-
The leading Infectious Diseases deals by value since 2010
-
Most active Infectious Diseases dealmakers since 2010
The report includes deals for the following indications:
-
Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile,
Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B
Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter
Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus
(MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas
aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other
bacterial indications
-
Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth
disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1
(Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio,
Respiratory syncytial virus (RSV), Zika, plus other viral indications.
-
Parasitic
-
Fungal: Nail Psoriasis, Onychomycosis (Nail infection), plus other
fungal indications
-
Tropical: African trypanosomiasis (Sleeping sickness), Dengue fever,
Malaria, West Nile Virus, Yellow fever, plus other tropical indications
Analyzing actual contract agreements allows assessment of the
following:
-
What are the precise rights granted or optioned?
-
What is actually granted by the agreement to the partner company?
-
What exclusivity is granted?
-
What is the payment structure for the deal?
-
How are the sales and payments audited?
-
What is the deal term?
-
How are the key terms of the agreement defined?
-
How are IPRs handled and owned?
-
Who is responsible for commercialization?
-
Who is responsible for development, supply, and manufacture?
-
How is confidentiality and publication managed?
-
How are disputes to be resolved?
-
Under what conditions can the deal be terminated?
-
What happens when there is a change of ownership?
-
What sublicensing and subcontracting provisions have been agreed?
-
Which boilerplate clauses does the company insist upon?
-
Which boilerplate clauses appear to differ from partner to partner or
deal type to deal type?
-
Which jurisdiction does the company insist upon for agreement law?
For more information about this report visit http://www.researchandmarkets.com/research/dsqj9z/global_infectious
View source version on businesswire.com: http://www.businesswire.com/news/home/20170227005705/en/
[ Back To TMCnet.com's Homepage ]
|